Three years of benefit assessments in IQWiG - taking stock
PD Dr. Stefan Lange
Introduction to the topic "Replication of study results?
Prof. Dr. Ralf Bender
Pivotal studies: Why do the regulatory authorities usually require that study results be replicated?
Dr. Armin Koch (Federal Institute for Drugs and Medical Devices, BfArM)
Decision approaches and statistical foundations for the cost-benefit assessment in comparison with confirmatory approval studies
Friedhelm Leverkus (Pfizer)